While there is consensus that anterior cruciate ligament reconstruction (ACLR) is the best treatment to provide near normal laxity after anterior cruciate ligament (ACL) rupture in an active person, the superior graft choice, fixation method, and surgical technique continue to be debated. Autograft tissue continues to be the most common choice overall, with regional variations favoring bone--patella tendon--bone (BPTB) over hamstrings in some parts of North America^[@bibr17-1941738115579030]^ and vice versa internationally.^[@bibr11-1941738115579030]^ In contrast, the use of allograft tissue is less common. Allograft is preferred by 11% of surgeons in international survey^[@bibr11-1941738115579030]^ and 22% in the United States.^[@bibr17-1941738115579030]^

There are advantages and disadvantages to each graft choice. Disadvantages of using autograft tissue include donor site morbidity, such as weakness and loss of knee flexion with hamstring autograft,^[@bibr53-1941738115579030]^ weakness of the quadriceps mechanism with BPTB,^[@bibr53-1941738115579030]^ variable graft sizes with hamstring tendon,^[@bibr47-1941738115579030]^ and patella fracture or anterior knee pain with BPTB.^[@bibr53-1941738115579030]^ Potential advantages of decreased operative time, consistent graft sizes, and lack of donor site morbidity make allograft tissue an attractive option for surgeons. However, increased cost, delayed incorporation of allograft tissue as compared with autograft,^[@bibr68-1941738115579030]^ and possible disease transmission^[@bibr54-1941738115579030]^ are potential disadvantages.

One previous meta-analysis of level 2 and 3 studies comparing primary BPTB autograft and BPTB allograft ACLR found a 5.03 times higher odds of graft rupture for patients undergoing allograft ACLR. However, if irradiated or chemically processed allografts were excluded, they found no statistically significant difference.^[@bibr34-1941738115579030]^ Another meta-analysis reported a 5% failure prevalence for autografts compared with a 14% failure prevalence for allografts (*P* \< 0.01).^[@bibr63-1941738115579030]^ Two systematic reviews comparing autograft with allograft ACLR did not find a statistically significant difference in failure prevalence between autograft and allograft ACLR.^[@bibr9-1941738115579030],[@bibr21-1941738115579030]^ While some studies have reviewed failure prevalence of autograft ACLR and allograft ACLR in patients with a higher level of activity, until recently, there has not been a comparison of allograft and autograft ACLR in young patients.^[@bibr3-1941738115579030],[@bibr5-1941738115579030]^ In a large prospective, multisite cohort study, Kaeding et al^[@bibr30-1941738115579030]^ demonstrated a higher revision prevalence for allograft that was most clinically significant in younger patients. From these data, for example, a 14-year-old was estimated to have a 22% risk of revision with allograft compared with a 6.6% chance for autograft.

The purpose of the current systematic review is to determine whether there is a difference in failure prevalence between allograft and autograft ACLR in young and highly active patients.

Materials and Methods {#section10-1941738115579030}
=====================

Literature Search {#section11-1941738115579030}
-----------------

A literature search of the EMBASE, MEDLINE, and Cochrane trials registry databases (from 1980 to the fourth week of October 2014) was conducted using keywords in combination "auto\$", "allo\$", and "anterior cruciate ligament" for EMBASE and "autog\*", "allog\*", and "anterior cruciate ligament" for MEDLINE and Cochrane. The only limit for the search was humans for all databases.

All titles and abstracts were reviewed, and if the study design was comparative and included any clinically relevant outcome (see criteria below), the full article was retrieved for the selection process. Systematic reviews from our search were retrieved, and their references were reviewed for any additional studies that could be included. An automatic alert option for MEDLINE was used that alerted the author by email if any articles were newly available through the database, which satisfied the search keywords in combination. This option was not available in EMBASE.

Eligibility Criteria {#section12-1941738115579030}
--------------------

For inclusion, a study had to be a therapeutic study design comparing allograft with autograft isolated ACL reconstruction, and either prospective or retrospective (level of evidence \[LOE\] 1, 2, and 3). The primary outcome of the study had to be failure of ACLR with an acceptable definition such as revision, magnetic resonance imaging (MRI) confirmation of rupture, and Lachman 2+ or instrumented laxity measurement \>5 mm side-to-side. Each study had to meet all inclusion criteria including: (1) appropriate study population (competitive athletes \[active military, mean Marx score \>12, varsity (college), semiprofessional, or professional\] or patients \<25 years old or stratified age groups for outcomes, if older patients included), (2) correct procedure (unilateral primary ACLR); (3) correct intervention being studied (autograft compared with allograft); (4) any relevant outcomes included (patient-reported outcomes, physical examination, reoperation, or failure); (5) minimum follow-up duration (2 years); and (6) minimum study size (15 patients in each treatment arm). Any study that failed to meet all of the above inclusion criteria was excluded. All case series (LOE 4) were excluded. Average follow-up of 2 years was not sufficient for inclusion. A study was also excluded if data from the same patients were included in another study with longer follow-up, in favor of the latter study. Abstracts presented at conferences but not published in peer-reviewed literature were also excluded. Concurrent meniscal or articular cartilage surgery was not an inclusion/exclusion criteria.

Study Selection {#section13-1941738115579030}
---------------

Two reviewers screened the titles and abstracts generated by the literature search for eligibility. If there was any uncertainty or ambiguity regarding eligibility, the study was included for full-text review. The reviewers independently assessed each full report to determine whether inclusion criteria were met. Disagreements were resolved by discussion with the senior author, when necessary. Journal, author name, and institution were not masked at any stage.

Data Extraction {#section14-1941738115579030}
---------------

Two reviewers extracted relevant data from each included study and recorded them into worksheet tables. Data collected in the worksheets included first author, journal and year in which the study was published, level of evidence, number of patients, follow-up duration, source of the autograft and allograft, allograft sterilization method if known, percentage of failures for each group, and study definition of graft failure. A comments section was included for any other relevant data particular to each study. All abstracted outcome data were entered into a meta-analysis software package (RevMan version 5.1; The Cochrane Collaboration) for pooled analysis.

Assessment of Risk of Bias in Eligible Studies {#section15-1941738115579030}
----------------------------------------------

The checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT^[@bibr8-1941738115579030]^) was used to evaluate the quality of included randomized controlled trials (RCTs). The CLEAR NPT is a validated quality assessment tool used to examine the adequacy of 10 key elements of an RCT. The Newcastle-Ottawa Scale^[@bibr86-1941738115579030]^ (NOS) was used to evaluate the quality of eligible prospective and retrospective cohort studies. The NOS assesses each study on 3 domains: selection, comparability, and outcome. Two reviewers independently assessed the methodological quality of eligible studies. Any disagreements were resolved with consensus discussion.

Statistical Analysis {#section16-1941738115579030}
--------------------

Descriptive statistics were calculated with categorical data presented as frequency with percentages and continuous data as mean ± SD. Weighted means with their corresponding SDs were calculated for all parameters. Pooled risk ratios (RRs) were calculated for dichotomous outcomes, while mean differences were calculated for continuous outcomes. Ninety-five percent CIs were reported for all point estimates. The Cochrane χ^2^ test for homogeneity (ie, Q test, *P* \< 0.10) was used to test for heterogeneity, while the *I*^2^ test was used to quantify heterogeneity.^[@bibr12-1941738115579030]^ To assess for potential publication bias, we constructed a funnel plot for each outcome analyzed (see Appendix Figure 1, available at <http://sph.sagepub.com/content/by/supplemental-data>).

We pooled data from eligible studies using a random effects model because of the anticipated heterogeneity across studies with respect to surgical technique, allograft/autograft type, and allograft sterilization method. We planned an a priori subgroup analysis of graft failure prevalence based on sterilization method (irradiation vs no irradiation), autograft type (BPTB vs quadrupled hamstring \[QHS\]), and level of evidence (1 and 2 vs 3). In circumstances where only a median and interquartile range were provided by the study, established statistical methods were used to obtain imputed means and SDs.^[@bibr26-1941738115579030]^ In one case, the author was contacted directly via email correspondence to provide SDs where imputation was not possible.^[@bibr2-1941738115579030]^

Results {#section17-1941738115579030}
=======

Literature Search {#section18-1941738115579030}
-----------------

The computed literature search identified 874 studies for review ([Figure 1](#fig1-1941738115579030){ref-type="fig"}). After review of each study title and/or abstract, 63 studies were retrieved for full-text review. Six studies were excluded because data from the same patients were published in other studies with longer duration of follow-up.^[@bibr4-1941738115579030],[@bibr6-1941738115579030],[@bibr22-1941738115579030],[@bibr69-1941738115579030],[@bibr72-1941738115579030],[@bibr77-1941738115579030]^ Four studies were excluded because they were conference abstract presentations without peer-reviewed publication.^[@bibr44-1941738115579030],[@bibr57-1941738115579030],[@bibr71-1941738115579030],[@bibr74-1941738115579030]^ Nineteen articles were excluded because they included patients of all ages and did not stratify their outcomes by age.^[@bibr5-1941738115579030],[@bibr10-1941738115579030],[@bibr18-1941738115579030],[@bibr23-1941738115579030][@bibr24-1941738115579030]-[@bibr25-1941738115579030],[@bibr32-1941738115579030],[@bibr38-1941738115579030],[@bibr42-1941738115579030],[@bibr49-1941738115579030],[@bibr56-1941738115579030],[@bibr61-1941738115579030],[@bibr62-1941738115579030],[@bibr66-1941738115579030],[@bibr76-1941738115579030],[@bibr78-1941738115579030][@bibr79-1941738115579030]-[@bibr80-1941738115579030],[@bibr83-1941738115579030]^ Twenty-one studies were excluded because duration of follow-up was less than 2 years.^[@bibr1-1941738115579030],[@bibr13-1941738115579030],[@bibr14-1941738115579030],[@bibr31-1941738115579030],[@bibr35-1941738115579030],[@bibr39-1941738115579030][@bibr40-1941738115579030]-[@bibr41-1941738115579030],[@bibr43-1941738115579030],[@bibr51-1941738115579030],[@bibr52-1941738115579030],[@bibr58-1941738115579030],[@bibr65-1941738115579030],[@bibr70-1941738115579030],[@bibr73-1941738115579030],[@bibr75-1941738115579030],[@bibr84-1941738115579030],[@bibr87-1941738115579030],[@bibr89-1941738115579030][@bibr90-1941738115579030]-[@bibr91-1941738115579030]^ Three studies were excluded because they did not report on failure (2 reported on muscle strength and 1 on transplantation safety).^[@bibr37-1941738115579030],[@bibr50-1941738115579030],[@bibr55-1941738115579030]^ One study was excluded for not meeting the minimum treatment arm size of 15 patients.^[@bibr16-1941738115579030]^ Two studies did not satisfy the correct procedure requirement.^[@bibr46-1941738115579030],[@bibr81-1941738115579030]^ Seven studies fulfilled the inclusion criteria, including 1 RCT^[@bibr7-1941738115579030]^ (level 1), 2 prospective cohort studies^[@bibr30-1941738115579030],[@bibr59-1941738115579030]^ (level 2), and 4 retrospective cohort studies^[@bibr2-1941738115579030],[@bibr3-1941738115579030],[@bibr19-1941738115579030],[@bibr20-1941738115579030]^ (level 3).

![Flow diagram summarizing the literature search, screening, and selection process.](10.1177_1941738115579030-fig1){#fig1-1941738115579030}

General Study Characteristics {#section19-1941738115579030}
-----------------------------

A total of 1016 participants were enrolled in the 7 eligible studies, including 463 treated with QHS autograft, 325 treated with BPTB autograft, and 228 treated with various allografts. All 7 studies that met inclusion criteria were conducted in the United States and enrolled patients undergoing ACLR between 1998 and 2012. Four studies involved a single surgeon.^[@bibr2-1941738115579030],[@bibr3-1941738115579030],[@bibr7-1941738115579030],[@bibr19-1941738115579030]^ The mean age of participants across all studies was 21.7 years. Four of the studies only included patients younger than 25 years.^[@bibr2-1941738115579030],[@bibr19-1941738115579030],[@bibr20-1941738115579030],[@bibr59-1941738115579030]^ Two studies included patients older than 25 years; however, the results were stratified by age.^[@bibr3-1941738115579030],[@bibr30-1941738115579030]^ The last study had an average age of 28.6 years, but still met the criteria for inclusion as the study participants were military cadets.^[@bibr7-1941738115579030]^ Patient sex was reported in 5 studies^[@bibr2-1941738115579030],[@bibr7-1941738115579030],[@bibr19-1941738115579030],[@bibr20-1941738115579030],[@bibr59-1941738115579030]^ of the 7, among which 281 of 442 patients (64%) were men. The mean follow-up was reported for 4 studies^[@bibr2-1941738115579030],[@bibr7-1941738115579030],[@bibr19-1941738115579030],[@bibr20-1941738115579030]^ and ranged from 24 to 51 months. The other 3 studies did not report a mean follow-up. All studies reported the graft failure prevalence after ACLR. The specific definitions used to identify graft failure in each included study are listed in [Table 1](#table1-1941738115579030){ref-type="table"}, along with other baseline patient characteristics.

###### 

Baseline characteristics for all eligible studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author   Journal           Year   LOE   Sample Size (% )   Minimum Follow-up, mo   Autograft Type   Allograft Type/Sterilization Method                                                                                                                                                Definition of Graft Failure                                                                            Autograft Failure, %   Allograft Failure, %   Comments
  -------------- ----------------- ------ ----- ------------------ ----------------------- ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Barber         *Arthroscopy*     2014   III   81 (49)            24                      BPTB             BPTB; no chemical processing or irradiation                                                                                                                                        Subsequent ACL revision surgery; 2+ Lachman; positive pivot-shift; side-to-side KT difference \>5 mm   9.4                    7.1                    Allografts from MTF (Edison, NJ)

  Barrett        *AJSM*            2011   III   224 (NR)           24                      BPTBQHS          Tibialis posterior or BPTB; not specified                                                                                                                                          2+ Lachman; positive pivot shift; side-to-side difference \>5 mm                                       BPTB: 11.8QHS: 25      29.2                   Did not comment on allograft type or sterilization processDivided based on age (\< or \>25 years)

  Bottoni        *OJSM*            2014   I     97 (89)            120                     QHS              Tibialis posterior; aseptically processed and fresh frozen without terminal irradiation                                                                                            Requiring ACL revision surgery                                                                         8.3                    26.5                   Allografts from MTF (Edison, NJ)US Military cadets

  Ellis          *Arthroscopy*     2012   III   79 (38)            24                      BPTB             BPTB; patented BioCleanse formula (RTI Biologics) or 1.0-1.3 rad (AlloSource)                                                                                                      Requiring ACL revision surgery                                                                         3                      35                     Allografts from 2 separate tissue banks \[failures\] including: RTI Biologics \[3/7\] and AlloSource \[4/7\]

  Engelman       *AJSM*            2014   III   73 (55)            24                      QHS              Tibialis anterior (n = 11) or tibialis posterior (n = 23) or peroneal tendon (n = 4); patented BioCleanse formula (RTI Biologics) or \<2 mrad irradiation (JRF, AlloSource, MTF)   Requiring ACL revision surgery and/or MRI confirmed ACL graft failure                                  11.43                  28.95                  Allografts from 4 separate tissue banks (failures) including: RTI Biologics (8/11), AlloSource (2/11), JRF (0/11), MTF (1/11)

  Kaeding        *Sports Health*   2011   II    340 (NR)           24                      QHS              Predominantly fresh frozen tibialis anterior, tibialis posterior, Achilles tendon, or BPTB; some irradiated \<2.5 mrad                                                             Requiring ACL revision surgery within 2 years of primary ACL reconstruction                            6.3                    18.9                   Ad hoc analysis could not identify tissue bank, allograft type, or processing/irradiation status as a significant variable for retear\
                                                                                                                                                                                                                                                                                                                                                                                                                                                    Included revisions (10.3%)

  Pallis         *AJSM*            2012   II    122 (75)           24                      BPTB\            Unavailable                                                                                                                                                                        Requiring ACL revision surgery                                                                         BPTB: 11.5QHS: 13.3    43.8                   No information on allograft type or sterilizationUS Military cadets
                                                                                           QHS                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACL, anterior cruciate ligament; *AJSM, American Journal of Sports Medicine*; BPTB, bone--patellar tendon--bone; JRF, Joint Restoration Foundation; LOE, level of evidence; MRI, magnetic resonance imaging; MTF, Musculoskeletal Tissue Foundation; NR, not reported; *OJSM, Orthopaedic Journal of Sports Medicine*; QHS, quadrupled hamstring.

Graft Choice and Treatment {#section20-1941738115579030}
--------------------------

Graft choice was decided by the patient, after a discussion with the surgeon regarding the risks and benefits of both options in 5 studies.^[@bibr2-1941738115579030],[@bibr3-1941738115579030],[@bibr19-1941738115579030],[@bibr20-1941738115579030],[@bibr30-1941738115579030]^ However, 1 study mentioned that the authors did not recommend allografts to their patients prior to 2002, although they enrolled from 1998 to 2009.^[@bibr19-1941738115579030]^ The study of military cadets^[@bibr59-1941738115579030]^ did not comment on graft choice decision as the ACLR was performed prior to matriculation and therefore prior to enrollment in their study. In the RCT,^[@bibr7-1941738115579030]^ patients were randomly assigned to treatment groups.

Two of the 7 included studies used fresh frozen allografts that did not undergo chemical processing or irradiation.^[@bibr2-1941738115579030],[@bibr7-1941738115579030]^ Chemical processing using BioCleanse (RTI Biologics) or irradiation with \<2 mrad^[@bibr20-1941738115579030]^ or 1.0 to 1.3 rad^[@bibr19-1941738115579030]^ was used in 2 studies. Another study^[@bibr30-1941738115579030]^ predominantly used fresh frozen allografts; however, some patients were also treated with irradiated grafts (\<2.5 mrad). The 2 remaining studies^[@bibr3-1941738115579030],[@bibr59-1941738115579030]^ did not specify how allografts were treated.

Surgical Technique {#section21-1941738115579030}
------------------

Drilling of the femoral tunnel was carried out using the transtibial technique in 3 studies,^[@bibr2-1941738115579030],[@bibr3-1941738115579030],[@bibr7-1941738115579030]^ the 2-incision rear-entry technique in 1 study,^[@bibr19-1941738115579030]^ the anteromedial portal technique in 1 study,^[@bibr20-1941738115579030]^ and a combination of techniques in 1 study.^[@bibr30-1941738115579030]^ Participants had undergone ACLR prior to enrollment in 1 study and technique was not specified.^[@bibr59-1941738115579030]^

Study Quality {#section22-1941738115579030}
-------------

The only RCT included in the current review reported adequate allocation concealment; however, there was some uncertainty regarding the generation of the allocation sequence and whether the intention-to-treat principle was used for statistical analysis. In general, the cohort studies (prospective and retrospective) had well-matched cohort and control groups (within studies). They were comparable with respect to important demographic variables (ie, age) and surgical technique (within studies). The complete results of the methodological quality assessment using the CLEAR NPT and NOS are presented in [Tables 2](#table2-1941738115579030){ref-type="table"} and [3](#table3-1941738115579030){ref-type="table"}, respectively.

###### 

Methodological quality assessment for the one eligible randomized controlled trial included in the study using the CLEAR NPT guidelines

  Primary Author (Study Year)   CLEAR NPT Criterion[\*](#table-fn3-1941738115579030){ref-type="table-fn"}                                       
  ----------------------------- --------------------------------------------------------------------------- --- --- --- --- --- --- --- --- --- ---------------------------------------------------------------------------------------------------------------------
  Bottoni (2014)                U                                                                           Y   Y   Y   Y   Y   Y   Y   Y   U   1\. No description of allocation sequence generation10. Uncertain whether intention-to-treat principle was followed

CLEAR NPT, checklist to evaluate a report of a nonpharmacological trial; N, no; U, unclear; Y, yes.

1\. Adequate generation of allocation sequence. 2. Treatment allocation concealed. 3. Details of each intervention available. 4. Expertise similar in each arm. 5. Participant adherence assessed. 6. Adequate participant blinding. 7. Care providers blinded. 8. Outcome assessors adequately blinded. 9. Similar follow-up between groups. 10. Used intention-to-treat analysis.

###### 

Methodological quality assessment of the 6 eligible (prospective and retrospective) included cohort studies using the Newcastle-Ottawa Scale

                            Newcastle-Ottawa Scale Criterion                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Barber (2014) \[III\]     [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}     0                                                        [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}
  Barret (2011) \[III\]     [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}     [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}
  Ellis (2012) \[III\]      [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*\*](#table-fn4-1941738115579030){ref-type="table-fn"}   0                                                        [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}
  Engelman (2014) \[III\]   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   0
  Kaeding (2011) \[II\]     [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}
  Pallis (2012) \[II\]      [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}     [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}   [\*](#table-fn4-1941738115579030){ref-type="table-fn"}

Star (\*) = item present. Maximum 1 star (\*) for the Selection and Outcome components. Maximum 2 stars (\*\*) for the Comparability component.

Primary Outcome {#section23-1941738115579030}
---------------

### Failure {#section24-1941738115579030}

The overall pooled graft failure prevalence across all patients included in this review was 13.9% (133/1016). The pooled graft failure prevalence for patients undergoing QHS autograft, BPTB autograft, and allograft was 9.5% (44/463), 9.8% (32/325), and 25.0% (57/228), respectively. The combined failure prevalence of all autografts was 9.6% (76/788). A quantitative synthesis of all 7 studies demonstrated a statistically significant difference in the overall risk of graft failure favoring patients undergoing ACLR with autograft compared with allograft (7 studies; RR, 0.36; 95% CI, 0.24-0.53; *P* \< 0.00001; *I*^2^ = 16%) ([Figure 2](#fig2-1941738115579030){ref-type="fig"}). The number of patients undergoing ACLR who needed to be treated to benefit (NNTB) with autograft to prevent 1 episode of graft failure was 7 patients (95% CI, 5-10). The funnel plot did not demonstrate evidence of publication bias.

![Forest plot illustrating results of the pooled analysis for graft failure prevalence in patients who underwent anterior cruciate ligament reconstruction using autograft versus allograft.](10.1177_1941738115579030-fig2){#fig2-1941738115579030}

The prevalence of graft failure in patients receiving irradiated (low dose) versus nonirradiated allografts was 31.0% (18/58) and 19.5% (15/77), respectively. A subgroup analysis comparing graft failure prevalence between autografts and allografts with and without irradiation demonstrated a statistically significant difference favoring autografts over allografts with irradiation (2 studies; RR, 0.22; 95% CI, 0.06-0.85; *P* \< 0.03; *I*^2^ = 56%) ([Figure 3A](#fig3-1941738115579030){ref-type="fig"}). No statistically significant difference in graft failure was seen between autografts and allografts without irradiation (2 studies; RR, 0.57; 95% CI, 0.14-2.27; *P* \< 0.42) ([Figure 3B](#fig3-1941738115579030){ref-type="fig"}).

![(A) Forest plot depicting the pooled results for graft failure prevalence in patients who underwent anterior cruciate reconstruction using autograft versus irradiated allograft. (B) Forest plot depicting the pooled results for graft failure prevalence in patients who underwent anterior cruciate ligament reconstruction using autograft versus nonirradiated allograft.](10.1177_1941738115579030-fig3){#fig3-1941738115579030}

An additional subgroup analysis was performed based on autograft type (QHS and BPTB) used versus allograft for ACLR. There was a statistically significantly difference in graft failure that favored the QHS (5 studies; RR, 0.42; 95% CI, 0.28-0.63; *P* \< 0.0001; *I*^2^ = 7%) (see Appendix Figure 2A) and BPTB (4 studies; RR, 0.37; 95% CI, 0.17-0.81; *P* \< 0.01; *I*^2^ = 57%) (see Appendix Figure 2B) groups when compared independently with allograft ACLR.

Last, there was a statistically significant difference in the overall graft failure prevalence when the results from level 1 or level 2 studies were pooled alone (3 studies; RR, 0.31; 95% CI, 0.19-0.49; *P* \< 0.00001; *I*^2^ = 0%) (see Appendix Figure 3A) and when level 3 studies were pooled alone (4 studies; RR, 0.41; 95% CI, 0.18-0.93; *P* \< 0.03; *I*^2^ = 51%) (see Appendix Figure 3B). We noted greater precision around the pooled point estimate of higher level studies (level 1 or 2).

Secondary Outcomes {#section25-1941738115579030}
------------------

### Lysholm Score {#section26-1941738115579030}

A quantitative synthesis of the included studies did not demonstrate a statistically significant difference in the postoperative Lysholm scores among patients undergoing ACLR with an allograft compared with an autograft (3 studies; mean difference, 1.87 points; 95% CI, −0.44 to 4.18; *P* \< 0.11). This is illustrated in [Figure 4](#fig4-1941738115579030){ref-type="fig"}.

![Forest plot summarizing the pooled analysis for mean difference in Lysholm score in patients who underwent anterior cruciate ligament reconstruction using autograft versus allograft.](10.1177_1941738115579030-fig4){#fig4-1941738115579030}

Other Patient-Reported Outcomes {#section27-1941738115579030}
-------------------------------

Although a formal quantitative synthesis could not be performed on the Tegner activity scale,^[@bibr7-1941738115579030],[@bibr19-1941738115579030]^ International Knee Documentation Committee^[@bibr2-1941738115579030],[@bibr20-1941738115579030]^ (IKDC), Single Assessment Numeric Evaluation^[@bibr7-1941738115579030]^ (SANE), and Cincinnati score^[@bibr2-1941738115579030]^ because of the small number of reporting studies, none individually reported a statistically significant outcome.

Discussion {#section28-1941738115579030}
==========

This systematic review identified a clear difference in failure prevalence favoring primary ACLR performed with autograft tissue over allograft tissue in young (≤25 years of age) or highly active patients. The relationship was consistent whether all studies were included (level 3) or only those of highest quality, and demonstrated little publication bias. From these summary data, among patients younger than 25 years, for every 7 patients treated with autograft instead of allograft tissue, 1 failure would be prevented.

A lack of data among included studies on other outcomes, including patient-reported outcome measures, precluded meta-analysis of any outcome other than failure in our review. Three studies reported postoperative Lysholm scores, but quantitative synthesis of these data did not reveal any differences of statistical or clinical significance.

The earliest included study^[@bibr30-1941738115579030]^ was published in 2011 and served as hypothesis-generating for this review. Those results have been confirmed with the inclusion of 6 subsequent studies, many of which were published in the most recent calendar year. Previously published meta-analyses comparing allograft and autograft ACLR, however, offer mixed conclusions.^[@bibr9-1941738115579030],[@bibr21-1941738115579030],[@bibr27-1941738115579030],[@bibr33-1941738115579030],[@bibr34-1941738115579030],[@bibr63-1941738115579030],[@bibr82-1941738115579030],[@bibr88-1941738115579030]^ Although a higher rerupture prevalence for allograft was reported in some,^[@bibr34-1941738115579030],[@bibr63-1941738115579030],[@bibr88-1941738115579030]^ no previous analysis used age stratification or age criteria for inclusion. Some authors of prior systematic reviews on this topic have noted this limitation in the literature.^[@bibr9-1941738115579030],[@bibr15-1941738115579030],[@bibr48-1941738115579030]^ The small absolute difference^[@bibr30-1941738115579030]^ in revision prevalence between allograft and autograft in older patients may explain why previous systematic reviews that have included studies of patients over a large age range produced mixed results.

There are potential confounding factors in the relationship between age and graft choice. Registry data^[@bibr28-1941738115579030]^ have suggested that surgeons who use allograft tissue are more likely to be low volume and not fellowship trained. Although there is limited current evidence for a relationship between surgery volume and outcome in ACLR,^[@bibr45-1941738115579030]^ precedence exists in other areas of orthopaedic surgery.^[@bibr64-1941738115579030],[@bibr85-1941738115579030]^ The volume of surgeries performed at the centers in each of the included studies from this review is unknown.

One of the largest controversies in allograft ACLR relates to the treatment of the tissue. Some have suggested that the studies that have shown greater failure with allograft tissue either did not include sterilization method or used irradiated or chemical sterilization methods that could lead to higher failure. In our review, we noted a difference between irradiated allograft and autograft tissue that achieved statistical significance, and also a difference between nonirradiated grafts and autograft but that did not achieve statistical significance. Caution should be used in this interpretation, however, as this synthesis included a very small number of studies. Furthermore, the 2 studies included in this review that used irradiated grafts were small and both were level 3. Other literature has supported better clinical outcomes with irradiated grafts,^[@bibr60-1941738115579030]^ and 1 recent systematic review of soft tissue grafts that was not stratified by age showed no difference between nonirradiated allografts and autograft ACLR.^[@bibr36-1941738115579030]^ Considering the difference we have demonstrated between allograft and autograft in the young or highly active population, we believe the burden of proof remains on the fresh-frozen allograft user to demonstrate safety in a high-level clinical study.

Delayed revascularization and recellularization of allograft tissue in vivo may be one explanation for our study's findings. Animal models have demonstrated delayed revascularization^[@bibr67-1941738115579030]^ and poorer performance of allograft ACLR.^[@bibr29-1941738115579030]^ Delayed revascularization has also been demonstrated in humans using contrast-enhanced MRI in allograft ACLR compared with autograft ACLR at 6-month follow-up.^[@bibr55-1941738115579030],[@bibr91-1941738115579030]^

Disadvantages of this study must be considered, many of which relate to the available data on this topic. Our inclusion criteria was for young patients and those with high activity level, but not specifically for other factors that may increase risk of failure such as those with poor rehabilitation or muscular control. Two of the included studies^[@bibr7-1941738115579030],[@bibr19-1941738115579030]^ used only revision as the definition of failure, and this may have biased the results. We acknowledge there is no consensus definition of failure.

Conclusion {#section29-1941738115579030}
==========

The differences in failure prevalence that we observed between allograft and autograft reconstruction among young and highly active patients should provide caution to those involved in the orthopaedic care of these patients. There is a paucity of data in this patient population to determine whether this difference between autograft and allograft persists based on allograft sterilization methods.
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